Amgen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

01.04.17	Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY™ (romosozumab) (PR Newswire)
31.03.17	Amgen To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting (PR Newswire)
30.03.17	FDA Snubs MYL, Roche Wins FDA Panel Vote Hands Down, TNXP Falls After-hours (RTTNews)
29.03.17	FDA Grants Priority Review For Amgen's BLINCYTO® (blinatumomab) Supplemental Biologics License Application (PR Newswire)
29.03.17	Journal Of Clinical Oncology Publishes Data On BLINCYTO® (Blinatumomab) In High-Risk Patients With Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (PR Newswire)
28.03.17	Amgen Awards Three Golden Tickets for LabCentral Residency (PR Newswire)
24.03.17	FDA Approves First-ever Merkel Cell Carcinoma Drug, HTGM Riding High, FLXN Soars (RTTNews)
23.03.17	European Commission Approves AMGEVITA™ (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases (PR Newswire)
20.03.17	Lowering LDL Levels with Repatha(R) (evolocumab) Did Not Adversely Affect Cognitive Function in Landmark Phase 3 Study (PR Newswire)
20.03.17	Landmark Outcomes Study Shows that Repatha(R) (evolocumab) Decreases LDL-C to Unprecedented Low Levels and Reduces Risk of Cardiovascular Events with No New Safety Issues (PR Newswire)
20.03.17	AMGN On Watch, GALE Reports Positive Data, EBS Secures BARDA Contract (RTTNews)
19.03.17	Analyses Of PCSK9 Inhibitor Prescription Rejection Rates Demonstrate Significant Access Barriers For Appropriate Patients (PR Newswire)
19.03.17	Amgen: Low LDL Levels With Repatha Did Not Affect Cognitive Function In Study (RTTNews)
18.03.17	Lowering LDL Levels With Repatha® (Evolocumab) Did Not Adversely Affect Cognitive Function In Landmark Phase 3 Study (PR Newswire)
17.03.17	Amgen Says Repatha Reduces Risk Of Hard Major Adverse Cardiovascular Events (RTTNews)
17.03.17	Landmark Outcomes Study Shows That Repatha® (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk Of Cardiovascular Events With No New Safety Issues (PR Newswire)
16.03.17	Amgen To Present At The Oppenheimer Global Health Care Conference (PR Newswire)
16.03.17	The Most Promising Biotech Innovation of 2017 (PR Newswire)
14.03.17	Repatha® (Evolocumab) Four-Year Open-Label Follow-Up Study Published In 'JAMA Cardiology' (PR Newswire)
14.03.17	Amgen To Webcast Investor Meeting At Upcoming American College Of Cardiology Scientific Sessions (PR Newswire)
13.03.17	Amgen Reports Positive Top-line Results From Repatha Phase 3 Study - Quick Facts (RTTNews)
13.03.17	Repatha® (Evolocumab) Demonstrates Reduced Need For Apheresis In Patients With High LDL Cholesterol In Phase 3 Study (PR Newswire)
07.03.17	Amgen Announces 2017 Second Quarter Dividend (PR Newswire)
07.03.17	NICE Recommends Amgen's Vectibix® (panitumumab) for Metastatic Colorectal Cancer for Previously Untreated Patients (PR Newswire)
06.03.17	Amgen Highlights Landmark Repatha® (Evolocumab) Cardiovascular Outcomes Study Amongst Data To Be Presented At ACC.17 (PR Newswire)
03.03.17	Amgen Presents Overall Survival Data From KYPROLIS® (carfilzomib) Phase 3 ENDEAVOR Trial At 16th International Myeloma Workshop (PR Newswire)
02.03.17	Amgen To Present At The Cowen And Company 37th Annual Health Care Conference (PR Newswire)
01.03.17	BLINCYTO® (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy (PR Newswire)
01.03.17	Amgen To Present New KYPROLIS® (Carfilzomib) And XGEVA® (Denosumab) Data At The 16th International Myeloma Workshop (PR Newswire)
28.02.17	Amgen: Phase 3 Trial Results Confirm Superiority Of KYPROLIS Over Velcade (RTTNews)
28.02.17	Phase 3 Head-to-Head Trial Showed KYPROLIS® (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade® (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients (PR Newswire)
27.02.17	Biotech Stocks Facing FDA Decision In March (RTTNews)
21.02.17	Repatha® (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option (PR Newswire)
21.02.17	Immunotherapy Companies Leading the Charge for Treating Cancer (PR Newswire)
14.02.17	Amgen Submits SBLA For Blincyto - Quick Facts (RTTNews)
14.02.17	Amgen Submits Supplemental Biologics License Application For BLINCYTO® (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (PR Newswire)
09.02.17	Sanofi Says Appeals Court Grants Stay Of Permanent Injunction For Praluent (RTTNews)
08.02.17	FLXN Gets FDA Date, KTOV In Crosshairs, It's A Thumbs Up For AMGN (RTTNews)
08.02.17	FDA Approves Amgen's Parsabiv™ (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis (PR Newswire)
06.02.17	Technical Reports on Biotech Stocks -- Amgen, Array BioPharma, Merrimack Pharma, and Alexion Pharma (PR Newswire)
06.02.17	ESPR, MDCO Riding High, New Uses For MRK's Old Drug, DBVT In Full Smile(e) (RTTNews)
03.02.17	BetterInvesting Magazine Releases April Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use (PR Newswire)
03.02.17	Amgen Announces Appointment of Charles M. Holley Jr. to Board of Directors (PR Newswire)
02.02.17	Amgen: FOURIER Trial On Repatha Meets Its Primary Composite Endpoints (RTTNews)
02.02.17	Amgen Issues FY17 Guidance - Quick Facts (RTTNews)
02.02.17	Amgen Inc. Q4 Earnings Rise 9% (RTTNews)
02.02.17	Amgen Reports Fourth Quarter And Full Year 2016 Financial Results (PR Newswire)
02.02.17	Amgen Announces Repatha® (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

22.11.24		Handel in Frankfurt: TecDAX letztendlich in Grün
22.11.24		Gewinne in Frankfurt: SDAX zum Handelsende freundlich
22.11.24		EVOTEC-Aktie verliert zweistellig: US-Unternehmen Halozyme zieht Angebot für EVOTEC zurück
22.11.24		Optimismus in Frankfurt: SDAX steigt am Nachmittag
22.11.24		Optimismus in Europa: So entwickelt sich der Euro STOXX 50 am Freitagnachmittag
22.11.24		Börse Frankfurt in Grün: TecDAX am Freitagnachmittag mit grünem Vorzeichen

22.11.24

Handel in Frankfurt: TecDAX letztendlich in Grün

22.11.24

Gewinne in Frankfurt: SDAX zum Handelsende freundlich

22.11.24

EVOTEC-Aktie verliert zweistellig: US-Unternehmen Halozyme zieht Angebot für EVOTEC zurück

22.11.24

Optimismus in Frankfurt: SDAX steigt am Nachmittag

22.11.24

Optimismus in Europa: So entwickelt sich der Euro STOXX 50 am Freitagnachmittag

22.11.24

Börse Frankfurt in Grün: TecDAX am Freitagnachmittag mit grünem Vorzeichen